直肠间隔物在MR引导自适应放疗中的作用
研究回顾性分析20例局限期前列腺癌患者,其中10例放置直肠间隔物,比较间隔物组与无间隔物组及在线自适应与非自适应计划的剂量学差异和毒性。结果显示两组均无≥2级毒性,间隔物组在所有直肠剂量目标上显著获益,但MRgART的自适应特性可缩小部分剂量学差异,作者认为需更大样本研究确认。
要点
- 间隔物组与无间隔物组均未观察到≥2级泌尿生殖或胃肠道毒性。
- 间隔物组在所有直肠剂量目标上显著获益(p<0.0001),部分膀胱目标亦获益。
- 在线自适应计划中两组计划目标失败率相似,多数为0%至4%。
核心结论
- 该队列结果提示MRgART用于前列腺SABR安全有效,间隔物组与无间隔物组毒性率相当。
- 直肠间隔物虽提供剂量学优势,但MRgART的自适应特性可缩小部分剂量学差异,可能减少对侵入性间隔物放置的需求。
- 作者指出需更大患者人群的进一步研究来确认这些结果。
研究设计与样本
- 单中心回顾性分析,纳入20例在Unity MR-Linac上治疗的局限期前列腺癌患者,其中10例在治疗前放置直肠间隔物。
- 采用adapt-to-shape策略进行在线MRgART,并离线生成非自适应计划用于比较。
- 比较间隔物组与无间隔物组、在线自适应计划与非自适应计划的剂量学差异,并在治疗后3、6、12个月采用常见不良事件评价标准v5.0评估临床医生报告的泌尿生殖和胃肠道毒性。
主要发现
- 两组均未观察到≥2级毒性。
- 靶区剂量学结果相当:间隔物组D95%为36.3 Gy,无间隔物组为36.0 Gy(p=0.08)。
- 间隔物组在所有直肠剂量目标上均显示显著获益(p<0.0001),并在部分膀胱目标上获益(V40,p=0.03;V36,p=0.03)。
- 在线自适应计划中,间隔物组与无间隔物组达到计划目标的失败率相似,两组多数失败率范围为0%至4%。
临床怎么用
- 作者认为MRgART用于前列腺SABR安全有效,间隔物组与无间隔物组毒性率相当。
- 作者认为直肠间隔物虽提供剂量学优势,但MRgART的自适应特性可缩小部分剂量学差异,可能减少对侵入性间隔物放置的需求。
- 作者指出需更大患者人群的进一步研究确认这些结果。
局限性
- 原文为单中心回顾性分析,共20例患者。
- 作者指出需更大患者人群的进一步研究来确认这些结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The use of stereotactic ablative radiotherapy (SABR) for prostate cancer has increased significantly. However, SABR can elevate the risk of moderate gastrointestinal (GI) side effects. Rectal spacers mitigate this risk by reducing the rectal dose. This study evaluates the impact of rectal spacers in MR-guided adaptive radiotherapy (MRgART) for prostate SABR. MATERIALS AND METHODS: A retrospective analysis was conducted on twenty patients with localised prostate cancer treated on the Unity MR-Linac at a single centre. Half of the cohort (n = 10) had rectal spacers placed before treatment. The adapt-to-shape strategy was used for online MRgART, and non-adapted plans were later generated offline for comparison. Dosimetric assessments were made between spacer and no-spacer cohorts, and between online adapted and non-adapted plans. Clinician-reported outcomes for genitourinary (GU) and GI toxicity were assessed at 3-, 6-, and 12-months post-treatment using Common Terminology Criteria for Adverse Events v.5.0. RESULTS: No grade 2 or higher toxicity was observed in either cohort. Overall, the dosimetric analysis showed comparable results between the cohorts for target volumes, with D95% of 36.3 Gy in the spacer cohort and 36.0 Gy in the no-spacer cohort (p = 0.08). The spacer cohort demonstrated significant benefits in all rectal dose objectives (p < 0.0001) and in some bladder objectives (V40, p = 0.03; V36, p = 0.03). Failure rates for achieving planning objectives were similar between spacer and no-spacer groups for online adapted plans, with most rates ranging from 0 % to 4 % in both groups. CONCLUSION: The findings from this cohort suggest that MRgART is safe and effective for prostate SABR, with comparable toxicity rates in both spacer and no-spacer cohorts. While rectal spacers offer dosimetric advantages, the adaptive nature of MRgART can mitigate some dosimetric disparities, potentially reducing the need for invasive spacer placement. However, further studies with larger patient populations are needed to confirm these results.
引用
- Batumalai V, Crawford D, Picton M, et al. The impact of rectal spacers in MR-guided adaptive radiotherapy. Clin Transl Radiat Oncol. 2024. PMID: 39434803. doi:10.1016/j.ctro.2024.100872
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。